CN2430992Y - Coronary supporter with re-stenosis prevention action - Google Patents
Coronary supporter with re-stenosis prevention action Download PDFInfo
- Publication number
- CN2430992Y CN2430992Y CN 00226145 CN00226145U CN2430992Y CN 2430992 Y CN2430992 Y CN 2430992Y CN 00226145 CN00226145 CN 00226145 CN 00226145 U CN00226145 U CN 00226145U CN 2430992 Y CN2430992 Y CN 2430992Y
- Authority
- CN
- China
- Prior art keywords
- coronary artery
- coronary
- supporter
- artery bracket
- utility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The utility model provides a coronary artery supporter with a restenosis prevention action. The utility model is characterized in that the surface of the coronary artery supporter is coated with one layer of gelatin protein, and one layer of C-myc antisense oligonucleotide is adsorbed on the surface of the gelatin protein. Thus, the utility model has the action of preventing restenosis after the coronary artery operation. The coronary artery supporter has simple preparation, safe and convenient operation and persistent action of preventing restenosis after the coronary artery operation. The utility model is a quite ideal coronary artery supporter.
Description
This utility model relates to a kind of medical apparatus and instruments, particularly relates to the coronary stent of control arteria coronaria angiostenosis in a kind of implant into body arteria coronaria blood vessel.
Through the percutaneous transluminal coronary urethroptasty is a kind of effective ways for the treatment of coronary heart disease, but acute obturation and postoperative coronary restenosis problem are clinical problem demanding prompt solutions always in the art, since U.S. FDA in 1994 formally passes through the coronary artery bracket clinical practice, significantly reduced the restenosis rate that acute obturation in the art is closed And disease and reduced the postoperative arteria coronaria, coronary artery bracket is in wide clinical application.The coronary artery bracket of present clinical use mainly contains rustless steel and alloy material two classes.Platinum-iridium alloy in the alloy material has the better tissues compatibility and blood-clot resistance, and has good endurance and the advantage that is difficult for jackknifing, is a kind of comparatively ideal coronary artery bracket.Though these supports respectively have advantage, to reducing arteria coronaria postoperative restenosis rate certain effect is arranged, their common drawback is the restenosis problem that does not fundamentally solve arteria coronaria.The subject matter of arteria coronaria postoperative restenosis is the blood vessels of coronary arteries section smooth muscle neointimal hyperplasia of placing coronary artery bracket, has only the local smooth muscle neointimal hyperplasia of the arteria coronaria that suppresses the placement coronary artery bracket effectively could fundamentally solve postoperative coronary restenosis problem.
The purpose of this utility model provides a kind of coronary artery bracket with the control restenosis effect that suppresses the local smooth muscle neointimal hyperplasia of arteria coronaria.
The purpose of this utility model realizes in the following manner: a kind of coronary artery bracket with the effect of control restenosis, comprise coronary artery bracket, glutin and C-myc antisense oligonucleotide, it is characterized in that the coronary artery bracket surface scribbles one deck glutin, glutin surface adsorption one deck C-myc antisense oligonucleotide, described coronary artery bracket is the platinum-iridium alloy support.
Embodiment further describes this utility model below in conjunction with accompanying drawing:
Fig. 1 is the sketch map of a kind of platinum-iridium alloy coronary artery bracket embodiment of the present utility model.
Fig. 2 is the sketch map of the transversal section of a kind of platinum-iridium alloy coronary artery bracket of the present utility model.
1, platinum-iridium alloy material
2, glutin
3, C-myc antisense oligonucleotide
The coronary artery bracket made from platinum-iridium alloy material 1 is the very good coronary artery bracket of present clinical practice, glutin 2 is a kind of good biological product, have adsorptivity preferably, C-myc antisense oligonucleotide 3 is a kind of biological product that have anticoagulation and suppress the effect of vascular smooth muscle neointimal hyperplasia.Utilize the adsorptivity of glutin that glutin 2 is spread upon the coronary artery bracket surface that platinum-iridium alloy material 1 is made, C-myc antisense oligonucleotide 3 is adsorbed on the glutin in the mode of soaking, promptly forms the coronary artery bracket with the effect of control restenosis of the present utility model.
Advantage of the present utility model is: when carrying out through the percutaneous transluminal coronary urethroptasty, coronary artery bracket of the present utility model is placed on according to a conventional method in the arteria coronaria blood vessel of diseased region, the C-myc antisense oligonucleotide 3 of coronary artery bracket surface glutin absorption arrives arteria coronaria vascular lesion position with coronary artery bracket, coronary artery bracket itself is to the arteria coronaria vasodilation and the supporting role of diseased region, the C-myc antisense oligonucleotide discharges gradually at arteria coronaria vascular lesion position, bring into play the effect of its anticoagulation and inhibition smooth muscle neointimal hyperplasia, reach and reduce acute obturation of arteria coronaria and the purpose of preventing and treating the arteria coronaria postoperative restenosis in the art.
Zoopery shows: use support of the present utility model and can obviously reduce proto-oncogene c-myc expression degree in the animal arteria coronaria smooth muscle cell, can obviously reduce animal arteria coronaria smooth muscle new intima area and average thickness, can increase the coronary lumen area, and do not increase the weight of histological inflammatory reaction, prove that coronary artery bracket of the present utility model has the better tissues compatibility and adsorptivity, can prevent and treat diseased region percutaneous transluminal coronary angioplasty postoperative restenosis effectively.
Claims (2)
1, a kind of coronary artery bracket with the effect of control restenosis comprises coronary artery bracket, glutin and C-myc antisense oligonucleotide, it is characterized in that the coronary artery bracket surface scribbles one deck glutin, glutin surface adsorption one deck C-myc antisense oligonucleotide.
2,, it is characterized in that coronary artery bracket is the platinum-iridium alloy support according to the described coronary artery bracket of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00226145 CN2430992Y (en) | 2000-03-02 | 2000-03-02 | Coronary supporter with re-stenosis prevention action |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00226145 CN2430992Y (en) | 2000-03-02 | 2000-03-02 | Coronary supporter with re-stenosis prevention action |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN2430992Y true CN2430992Y (en) | 2001-05-23 |
Family
ID=33590059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00226145 Expired - Fee Related CN2430992Y (en) | 2000-03-02 | 2000-03-02 | Coronary supporter with re-stenosis prevention action |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN2430992Y (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100413540C (en) * | 2002-09-03 | 2008-08-27 | 微创医疗器械(上海)有限公司 | Gene carrying rack and its producing method and use |
-
2000
- 2000-03-02 CN CN 00226145 patent/CN2430992Y/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100413540C (en) * | 2002-09-03 | 2008-08-27 | 微创医疗器械(上海)有限公司 | Gene carrying rack and its producing method and use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6309988B2 (en) | Medical device for dispersing drugs | |
| DE69729778T2 (en) | Stent for the dilation of stenotic damage of a blood vessel | |
| AU2003256540B2 (en) | Coated medical device | |
| JP3372950B2 (en) | Drug delivery system | |
| US5866561A (en) | Local delivery of estrogen for angiogenesis | |
| JP3485264B2 (en) | Biocompatible medical metal material to which a physiologically active substance is bound and method for producing the same | |
| JP3816802B2 (en) | Medical equipment | |
| JP2005531332A (en) | Hormone-coated stent to prevent stenosis or atherosclerosis | |
| CN106913916A (en) | A kind of application of degradable zinc-containing alloy implantation material in intravascular stent is prepared | |
| US20020182750A1 (en) | Intravascular apparatus method | |
| JP2006519623A (en) | Vascular stent or vascular graft coated or impregnated with protein tyrosine kinase inhibitor and method of use thereof | |
| CN104888282B (en) | A kind of degradable zinc-base micropore carried stent and preparation method thereof | |
| CA2154698A1 (en) | Therapeutic inhibitor of vascular smooth muscle cells | |
| US20170113068A1 (en) | Ultrasonic bath to increase tissue perfusion | |
| WO2018059167A1 (en) | Drug-coated balloon | |
| CN101485902B (en) | Biological degradable metal stent coated with rapamycin-probucol composite medicament | |
| BE1006819A7 (en) | Polyurethane coated prostheses (stents) FOR THE TREATMENT OF VESSEL CHOKES. | |
| CN2430992Y (en) | Coronary supporter with re-stenosis prevention action | |
| Swanson et al. | In vitro evaluation of vascular endothelial growth factor (VEGF)-eluting stents | |
| CN101239216A (en) | Novel sacculus dilating catheter | |
| CN209713964U (en) | A kind of sacculus for biological body vessel bifurcated lesions | |
| CN106890368A (en) | For the ureter bracket and preparation method of tumour targeted therapy | |
| Shiraki et al. | Effect of Short-Term Administration of High Dose L-Arginine on Restenosis After Percutaneous Transluminal Coronary Angioplasty (English text) | |
| JP2002320629A (en) | Medical care material to be embedded in vivo and medical care instrument | |
| Rosenfield et al. | Defining the next generation of drug-coated balloon technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |